The advantages and disadvantages of introducing a funded HPV vaccine for boys aged between 9 - 20 years

Abstract

Human Papillomavirus(HPV) vaccine has been internationally recognised to decrease the prevalence of HPV related diseases. Introduced to New Zealand with a female focus in 2008, the researcher of this study wanted to explore the advantages and disadvantages of providing a funded vaccination programme to males aged between the ages of 9-20 years.

Through the use of a systematic literature review, six articles were used for data extraction, synthesis and analysis to determine the advantages and disadvantages of introducing a funded vaccine for males.

Four emerging results were determined through the use of data extraction, analysis and synthesis. These were then presented in a narrative form to establish both advantages and disadvantages of introducing a funded vaccine programme for males. With discussion focused on the main findings and how that could fit to a New Zealand immunisation programme.

Good evidence was found to support that the HPV vaccine decreased HPV viruses (vaccinated types), however results also showed that extending vaccination to males could not, at this stage, be considered cost effective. Further evidence regarding the health benefits and cost effectiveness of providing a full funded vaccination to New Zealand males is required.